13 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
and will evaluate additional indications to maximize the potential of our drug development program. Our current product focus is on targets … in Schedule II of the Controlled Substances Act (CSA).
Research and Testing to Date
Ketamir-2
Preclinical Research Findings
In Silico Analysis of Targets
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
and will evaluate additional indications to maximize the potential of our drug development program. Our current product focus is on targets
424B1
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus with pricing info
12:59pm
the potential of our drug development program. Our current product focus is on targets that are well characterized in neurological diseases
S-1
xjhai5l7
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.5
31nja5pthpx21a1tgc9
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-10.5
jgh0u5
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
8l1twqufksh
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
zvxokinn
2 May 23
Draft registration statement (amended)
12:00am
DRS
gjikj
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next